SK Bioscience Advancing Bioscience Research and Development

SK Bioscience is a leading biotechnology company that's making significant strides in bioscience research and development. With a strong focus on innovation, the company is pushing the boundaries of what's possible in the field.

SK Bioscience has a robust pipeline of products in various stages of development, including vaccines and biologics. The company's expertise in vaccine development has led to the creation of several successful products.

One of the key areas SK Bioscience is advancing is in the field of mRNA technology. The company's research in this area has led to the development of novel vaccine candidates that have shown promising results in clinical trials.

SK Bioscience is a company that's making a big impact in the world of healthcare. They've successfully developed South Korea's first COVID-19 vaccine, 'SKYCovione', through global cooperation.

Their innovative technology has enabled them to develop a universal vaccine to prevent 'Sarbecovirus'. SK Bioscience has also developed the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu.

They've obtained WHO PQ (Pre-qualification) certification for SKYCellflu in 2019.

SK bioscience is a company that's dedicated to promoting human health from prevention to cure. They've developed some groundbreaking vaccines, including South Korea's first COVID-19 vaccine, 'SKYCovione', in collaboration with the Bill & Melinda Gates Foundation and other global partners.

The company has also developed a universal vaccine to prevent 'Sarbecovirus' and the world's first quadrivalent cell-cultured influenza vaccine, SKYCellflu, which received WHO PQ certification in 2019. This achievement demonstrates their commitment to innovation and global standards.

SK bioscience has successfully developed several other vaccines, including SKYZoster, the world's second shingles vaccine, and SkyVaricella, the world's second WHO PQ-certified chickenpox vaccine. These achievements show the company's expertise in vaccine development.

Their R&D pipeline is expanding through global partnerships with public and private institutions. They're planning to commercialize several new vaccines, including a pneumococcal conjugate vaccine, cervical cancer vaccine, typhoid conjugate vaccine, and rotavirus vaccine.

SK bioscience has also signed a contract to manufacture AstraZeneca's COVID-19 vaccine, further solidifying their position as a global hub for vaccine manufacturing.

For more insights, see: The Pinkfong Company

Our company's headquarters is located in the heart of downtown Los Angeles.

The exact address is 123 Main Street, Suite 400, Los Angeles, CA 90012.

The city's vibrant atmosphere and diverse community make it an ideal location for our business.

SK Bioscience is a biopharmaceutical company involved in biologics and vaccines. It provides contract development and manufacturing organization (CDMO) and contract manufacturing organization (CMO) services.

The company was founded in 2018 and is based in Gyeonggi-do, South Korea. SK Bioscience sells to the healthcare and pharmaceutical sectors.

SK Bioscience specializes in the research, development, and manufacture of vaccines, with a focus on global partnerships and contract manufacturing services. It has developed a diverse portfolio of vaccines and has engaged in numerous international collaborations to enhance vaccine accessibility worldwide.

The company has developed several key products and services, including SKYCellflu Quadrivalent, a cell culture-based influenza vaccine, and SKYCovione, South Korea's first domestically developed COVID-19 vaccine.

If this caught your attention, see: List of Companies of South Korea

SK Bioscience has filed 23 patents, showcasing the company's commitment to innovation and intellectual property.

The patents were filed on February 6, 2020, and have been granted, indicating a successful application process.

One notable patent is for a "Streptococcus pneumoniae antiserum without cross-reactivity and method for producing the same", which was granted on March 18, 2025.

This patent is related to vaccines, HLA-B alleles, immunology, the immune system, and vaccination, highlighting the intersection of these fields in biotechnology.

Here's a breakdown of the patent's details:

SK Bioscience has made significant strides in vaccine development, with a focus on producing high-quality vaccines for global markets.

The company's vaccine portfolio includes COVID-19 vaccines, with their COVID-19 vaccine candidate, SKYCovione, having completed Phase 3 clinical trials in South Korea.

SK Bioscience's commitment to vaccine development is evident in their partnership with the Bill and Melinda Gates Foundation to develop a COVID-19 vaccine for low- and middle-income countries.

Explore further: Lotte Tour Development

The company's COVID-19 vaccine candidate has shown promising results, with a vaccine efficacy rate of 85.6% in Phase 3 clinical trials.

SK Bioscience's manufacturing capabilities have been expanded to meet the growing demand for vaccines, with a new facility in the Republic of Korea capable of producing up to 200 million doses per year.